Hypertension
Conference Coverage
Baxdrostat slashes BP in resistant hypertension: BrigHTN
The novel agent lowers aldosterone activity without the off-target inhibition of cortisol synthesis that has thwarted previous drug candidates,...
Conference Coverage
Sham-controlled renal denervation trial for hypertension is a near miss
The SPYRAL HTN–ON MED trial missed its primary endpoint, likely caused in part by imbalances in medication use.
Conference Coverage
Tirzepatide cuts BP during obesity treatment
“The large effects on ambulatory 24-hour blood pressure raise the possibility that there may be important long-term benefits of [tirzepatide] on...
Conference Coverage
Four-drug combo gets BP down in one step: QUARTET-USA
The combination product containing quarter doses of four different drugs reduced blood pressure by almost 5 mm Hg more than a standard dose of one...
Conference Coverage
Study sheds new light on RAS inhibitors’ role for advanced CKD
“The results of this trial will inform future clinical practice worldwide and guideline recommendations.”
Conference Coverage
Diuretic agents equal to prevent CV events in hypertension: DCP
Cardiovascular events were nearly identical with two different hypertension drugs in the randomized Diuretic Comparison Project trial.
Conference Coverage
AHA 2022 to recapture in-person vibe but preserve global reach
Planners see the meeting’s Chicago return as a hybrid after 2 years relegated to cyberspace as a chance for first impressions on some just...
From the Journals
Diabetes becoming less potent risk factor for CVD events
Diabetes is no longer equal to cardiovascular disease as a risk factor for cardiovascular events, according to a population-based study in Ontario...
From the Journals
Finerenone benefits T2D across spectrum of renal function
Finerenone treatment of people with type 2 diabetes and albuminuria improved outcomes, compared with placebo regardless of renal functional status...
From the Journals
New deep dive into Paxlovid interactions with CVD meds
The review tackles potential drug-drug interactions with the antiviral drug and today’s most commonly prescribed cardiovascular drugs.
From the Journals
Cardiac biomarkers track with hormone therapy in transgender people
A pilot study spotlights differences in two common biomarkers of cardiac disease as well as the need for greater inclusivity in cardiovascular...